Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Regeneron Pharmaceuticals (NASDAQ:REGN) on Friday topped Street forecasts with its Q2 financials, thanks mainly to U.S. sales ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

The FDA had set an Aug. 19 target action date for the company's application, which was seeking a green light for Eylea HD for the treatment of macular edema following retinal vein occlusion and for ...

EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ -- ...

U.S. sales of the drug, Eylea, jumped 44% to $781 million compared with the prior-year quarter. Regeneron said it expects U.S. sales of Eylea to grow between 20% to 25% for the year, up from its ...